1. Home
  2. TNXP vs LAES Comparison

TNXP vs LAES Comparison

Compare TNXP & LAES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TNXP
  • LAES
  • Stock Information
  • Founded
  • TNXP 2007
  • LAES 2022
  • Country
  • TNXP United States
  • LAES Switzerland
  • Employees
  • TNXP N/A
  • LAES N/A
  • Industry
  • TNXP Biotechnology: Pharmaceutical Preparations
  • LAES Semiconductors
  • Sector
  • TNXP Health Care
  • LAES Technology
  • Exchange
  • TNXP Nasdaq
  • LAES Nasdaq
  • Market Cap
  • TNXP 15.1M
  • LAES 12.6M
  • IPO Year
  • TNXP N/A
  • LAES N/A
  • Fundamental
  • Price
  • TNXP $0.15
  • LAES $0.42
  • Analyst Decision
  • TNXP Strong Buy
  • LAES Strong Buy
  • Analyst Count
  • TNXP 2
  • LAES 1
  • Target Price
  • TNXP $53.50
  • LAES $1.75
  • AVG Volume (30 Days)
  • TNXP 25.4M
  • LAES 420.7K
  • Earning Date
  • TNXP 11-07-2024
  • LAES 09-25-2024
  • Dividend Yield
  • TNXP N/A
  • LAES N/A
  • EPS Growth
  • TNXP N/A
  • LAES N/A
  • EPS
  • TNXP N/A
  • LAES N/A
  • Revenue
  • TNXP $12,458,000.00
  • LAES $20,135,000.00
  • Revenue This Year
  • TNXP $62.53
  • LAES N/A
  • Revenue Next Year
  • TNXP $26.17
  • LAES N/A
  • P/E Ratio
  • TNXP N/A
  • LAES N/A
  • Revenue Growth
  • TNXP N/A
  • LAES N/A
  • 52 Week Low
  • TNXP $0.12
  • LAES $0.29
  • 52 Week High
  • TNXP $22.08
  • LAES $3.95
  • Technical
  • Relative Strength Index (RSI)
  • TNXP 35.86
  • LAES 43.44
  • Support Level
  • TNXP $0.13
  • LAES $0.37
  • Resistance Level
  • TNXP $0.18
  • LAES $0.54
  • Average True Range (ATR)
  • TNXP 0.02
  • LAES 0.05
  • MACD
  • TNXP 0.01
  • LAES -0.00
  • Stochastic Oscillator
  • TNXP 30.67
  • LAES 30.95

About TNXP Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.

About LAES SEALSQ Corp

SEALSQ Corp develops certified secure microcontrollers and implements post-quantum cryptography. The company develops solutions including post-quantum microchips and devices that can be used in a variety of applications, from multi-factor authentication, home automation, and IT network infrastructure to automotive, industrial automation, and control systems. Its vaultIC range offers a complete set of ready-to-use secure elements designed to implement embedded security for any kind of device with fast time-to-market and high flexibility. The company's products include VaultIC155, VaultIV18x, VaultIC292, and VaultIC40x. The company generates a majority of its revenue from North America.

Share on Social Networks: